Pregnancy risk auxiliary management method and system based on cardiovascular diseases

Abstract

The invention discloses a pregnancy risk auxiliary management method and system based on cardiovascular diseases, and relates to the technical field of medical auxiliary management. The pregnancy risk auxiliary management system comprises a system management module, an evaluation module, a follow-up visit management module, an information interaction module and a support database. The auxiliary management system can automatically generate targeted pregnancy risk assessment results and follow-up management suggestions according to related basic data of patients, so that the assessment and management efficiency of doctors and pharmacists on cardiovascular risks of patients receiving ART can be remarkably improved, and the follow-up management time is greatly saved; the accuracy, comprehensiveness and reliability of follow-up management suggestions can be remarkably improved, timely and effective cardiovascular disease related risk follow-up management suggestions can be provided in the pregnancy process, and the method is suitable for large-scale pregnancy risk auxiliary management based on cardiovascular diseases.

Description

Technical Field

[0001] The present invention relates to the field of medical technology, in particular to the field of medical assistance technology, and in particular to a method and system for assisting management of pregnancy risks based on cardiovascular diseases. Background Art

[0002] Assisted reproductive technology (ART) refers to the use of medical assistance to help infertile couples conceive, mainly including artificial insemination, in vitro fertilization-embryo transfer and its derivative technologies, such as intracytoplasmic sperm injection, preimplantation genetic testing, etc. Since the birth of the first in vitro fertilization baby (test tube baby) in 1978, ART technology has continued to develop and has become an important means of treating infertility.

[0003] In recent years, with the increasing number of ART applications, more and more studies have begun to focus on the potential link between assisted reproductive technology (ART) and cardiovascular disease (CVD). Some studies have shown that individuals conceived through ART may face a higher risk of cardiovascular disease. During the ART process, certain regimens that increase exogenous estrogen levels may induce a prothrombotic state and disrupt the renin-angiotensin-aldosterone system, which may lead to vascular endothelial damage and increase the risk of gestational hypertension.

[0004] With the continuous improvement of medical standards, more and more patients with cardiovascular disease or CVD risk factors are using or considering ART technology. However, although ART is well tolerated in most people, it is poorly tolerated in CVD patients, which may be related to the cardiovascular health status of CVD patients themselves.

[0005] Currently, there is limited reference material on the assessment and management of cardiovascular disease risks that may occur after ART and the risk of pregnancy in patients with cardiovascular disease after ART. This makes doctors and patients face greater uncertainty during pregnancy after ART, making it difficult to accurately assess and control cardiovascular disease risks. Therefore, it is particularly urgent to design a method and system for assessing and managing cardiovascular risks in patients undergoing assisted reproductive technology. Summary of the invention

[0006] The purpose of the present invention is to overcome the problem that the prior art is difficult to accurately assess and control the risk of pregnancy due to cardiovascular disease, and to provide a method and system for auxiliary management of pregnancy risk based on cardiovascular disease.

[0007] In order to achieve the above-mentioned invention object, the present invention provides a pregnancy risk auxiliary management system based on cardiovascular disease, including a system management module, an evaluation module, a follow-up management module, an information interaction module and a support database; Wherein, the system management module is used to assist in the basic maintenance and settings of the management system; The assessment module is used to assess the patient's pregnancy risk based on the patient-related basic data collected by the patient information interaction module, and output the pregnancy risk assessment result and the recommendation on whether to continue ART; the patient-related basic data includes at least one of basic information, liver and kidney function level, pregnancy symptoms and signs, and diagnosis and treatment plan; The follow-up management module is used to output follow-up management suggestions based on the patient's relevant basic data and pregnancy risk assessment results; The information interaction module includes a patient information interaction module and a physician information interaction module; The patient information interaction module is used to input patient-related basic data and receive the pregnancy risk assessment results output by the assessment module, the advice on whether to continue ART, and the follow-up management advice output by the follow-up management module; The physician information interaction module is used to receive and review the pregnancy risk assessment results output by the assessment module, the advice on whether to continue ART, and the follow-up management advice output by the follow-up management module; The supporting database is used to provide data support for the evaluation module and the follow-up management module.

[0008] The present invention provides an auxiliary management system for pregnancy risk based on cardiovascular disease. By specifically setting an assessment module that can assess the pregnancy risk of patients and a follow-up management module that can provide corresponding follow-up management suggestions based on the pregnancy risk assessment results, the auxiliary management system can automatically generate targeted pregnancy risk assessment results and follow-up management suggestions based on the patient's relevant basic data, thereby not only significantly improving the evaluation and management efficiency of cardiovascular risks of patients receiving ART by physicians and pharmacists, greatly saving follow-up management time; but also significantly improving the accuracy, comprehensiveness and reliability of follow-up management suggestions, which helps to provide more timely and effective follow-up management suggestions for related risks of cardiovascular diseases during pregnancy, and is suitable for large-scale application in auxiliary management of pregnancy risks based on cardiovascular diseases.

[0009] Among them, preferably, the system management module includes a data backup and recovery sub-module, a user authority setting sub-module and a pregnancy data recording sub-module; the user authority setting sub-module is used to grant login permissions according to set values ​​(such as physician or pharmacist level); the data backup and recovery sub-module is used to record data loss due to unexpected circumstances to ensure data integrity; the pregnancy data recording sub-module is used to record data information related to the pregnancy process of each patient to facilitate data backup, collation and review.

[0010] Preferably, the information interaction module includes an input module and a receiving and displaying module; the input module is used to input relevant data; the receiving and displaying module is used to receive and display relevant data; Among them, preferably, the physician information interaction module includes an obstetrician end, a cardiologist end and a pharmacist end; physicians can view, review and modify relevant data through the physician information interaction module.

[0011] Among them, preferably, the entry module includes an automatic import submodule and a custom entry module; the automatic import submodule is used to automatically import relevant information; the custom entry module is used for users to enter relevant information by themselves.

[0012] Preferably, the custom entry module includes an image recognition entry module and a manual entry module; the image recognition entry module refers to a functional module that can scan or take pictures, use OCR technology to automatically identify the text content in the picture and convert it into an editable text format, thereby realizing automatic entry; the manual entry module refers to a functional module that requires the user to enter information word by word through the keyboard to realize entry, and is suitable for scenarios that cannot be recognized by OCR or require high-precision proofreading.

[0013] Preferably, the manual input module can also be used by the patient to manually correct the data that cannot be recognized or is recognized incorrectly during the input process of the image recognition module, especially to correct the unit of the data.

[0014] Among them, preferably, the basic information includes the patient's name, age, ID number, previous medical history, previous medication history and drug allergy history; the symptoms and signs during pregnancy include gestational age data, dietary information, exercise information and test results; the diagnosis and treatment plan includes doctor's orders and medication plans; the liver and kidney function levels are evaluated based on clinical test data and patient basic information; specifically: the result is calculated using the creatinine clearance calculation formula, and the renal function level is judged according to the range of the result; the liver function level is judged using the Child-Pugh grading standard.

[0015] Preferably, the supporting database is used to store existing data information; the existing data information such as: drug interaction data, contraindications for medication for liver and kidney function, contraindications for medication during ART, contraindications for medication during pregnancy, and dietary precautions for pregnancy.

[0016] The drug interaction information is a database that records the synergistic or antagonistic effects between drugs when two or more drugs are used simultaneously or sequentially. This effect may change the efficacy of the drugs or increase the risk of adverse reactions, and also includes pharmacokinetic characteristics data; such as Lexicomp and Micromedex databases.

[0017] The liver and kidney function medication contraindications are a database that records the correspondence between liver and kidney function levels and related drug dosages, as well as related information such as medication contraindications, such as the rational medication system (MCDEX) database.

[0018] The contraindications to medication during ART are relevant databases that record contraindications to medication during ART, such as: Reprotox®, TERIS database (Teratogenic Risk Information System).

[0019] The pregnancy contraindications information is a database that records relevant information such as contraindications and dosage of medications during pregnancy, such as PLLR (Pregnancy and Lactation Labeling Rules).

[0020] The pregnancy lifestyle and diet precautions are data that record relevant precautions and suggestions for pregnant women on lifestyle, diet, etc. during pregnancy. The data comes from the comprehensive recommendations of the Chinese Nutrition Society, the American College of Obstetricians and Gynecologists, and the World Health Organization.

[0021] Among them, the pregnancy risk assessment results include: high-risk pregnancy, moderate-risk pregnancy and low-risk pregnancy; high-risk pregnancy means that the incidence of cardiovascular events is >20%, the maternal mortality rate is significantly increased, or the maternal and fetal complications are severely increased; moderate-risk pregnancy means that the incidence of cardiovascular events is 6-10%, the maternal mortality rate is slightly increased, or the maternal and fetal complications are moderately increased; low-risk pregnancy means that the incidence of cardiovascular events is 2-5%, the maternal mortality rate is not significantly increased, or the maternal and fetal complications are not increased or slightly increased.

[0022] Among them, preferably, the assessment module scores and grades the patient's relevant basic data based on the modified World Health Organization (mWHO) risk assessment standard, the ZAHARA score (cardiovascular risk prediction model during pregnancy) standard and the CARPREG score standard (congenital heart disease pregnancy risk assessment), and outputs the pregnancy risk assessment result according to the scoring and grading results; including: if the patient's mWHO risk grade is greater than or equal to grade III, the total score of the ZAHARA score is greater than 2 points, or the CARPREG score is greater than or equal to 1 point, then output a pregnancy risk assessment result of "high pregnancy risk"; if the patient's CARPREG score is less than 1 point, and the mWHO risk grade is grade II, or the total score of the ZAHARA score is less than 2 and greater than 0.5 points, then output a pregnancy risk assessment result of "medium pregnancy risk"; if the patient's CARPREG score is less than 1 point, and the mWHO risk grade is grade I and the total score of the ZAHARA score is less than or equal to 0.5 points, then output a pregnancy risk assessment result of "low pregnancy risk".

[0023] Preferably, the assessment module outputs a recommendation on whether to perform ART based on the pregnancy risk assessment result; including: if the pregnancy risk assessment result is "high risk of pregnancy", outputting a recommendation of "not recommending to continue with ART"; if the pregnancy risk assessment result is "medium risk of pregnancy and low risk of pregnancy", outputting a recommendation of "can continue with ART".

[0024] Among them, preferably, the follow-up management module includes a treatment management suggestion submodule, a medication suggestion submodule and a lifestyle and diet suggestion submodule.

[0025] Preferably, the follow-up management recommendations include treatment management recommendations, medication recommendations, and lifestyle and dietary recommendations.

[0026] Preferably, the treatment management recommendation submodule outputs treatment management recommendations based on the patient's pregnancy risk assessment results; including: if the pregnancy risk assessment result is a low risk of pregnancy, then outputting a recommendation of "conducting 1-2 pregnancy risk assessments during pregnancy"; if the pregnancy risk assessment result is a medium risk of pregnancy, then outputting a recommendation of "conducting a pregnancy risk assessment at least once every 3 months during pregnancy"; if the assessment result is a high risk of pregnancy, then outputting a recommendation of "not recommending continuing the pregnancy or conducting a pregnancy risk assessment once a month".

[0027] Preferably, the treatment management recommendations also include treatment management recommendations for patients with specific cardiovascular diseases (including: venous thromboembolism, hyperlipidemia, stroke and essential hypertension) or cardiovascular high risk factors (ischemic heart disease symptoms), including: If the patient has a history of venous thromboembolism after or without hormone exposure, the recommendation is output to "start thromboprophylaxis at the beginning of ovarian gonadotropin stimulation"; if ovarian hyperstimulation syndrome occurs, the recommendation is output to "start preventive anticoagulation therapy"; if the patient still develops venous thromboembolism during pregnancy after the above measures, the recommendation is output to "start therapeutic anticoagulation"; If the patient has a history of hyperlipidemia, the output is "all hyperlipidemia drugs can continue to be used during gamete retrieval (gamete (sperm and egg) retrieval is a key step in assisted reproductive technology, which refers to the acquisition of mature gametes through safe and effective methods for subsequent fertilization and embryo transfer operations). No special monitoring is required during assisted reproductive technology. During pregnancy, pay attention to monitoring atherosclerotic cardiovascular disease (ASCVD) that may be caused by hyperlipidemia." If ASCVD occurs during pregnancy, the output is "start ASCVD treatment"; If the patient has had a stroke before, the output is "the continuation or discontinuation of antiplatelet drugs should be determined based on the individual patient risk"; if the patient has another stroke during pregnancy, the output is "the treatment should be started based on the individual patient's stroke condition"; If the patient has a history of essential hypertension, the output is a suggestion of "optimizing blood pressure control to systolic blood pressure (SBP) below 130 mmHg and diastolic blood pressure (DBP) below 80 mmHg, and paying attention to monitoring for hypertensive disorders during pregnancy"; if the systolic blood pressure during pregnancy is higher than 155 mmHg, or the diastolic blood pressure is higher than 105 mmHg, the output is a suggestion of "starting antihypertensive treatment"; If the patient has or develops symptoms of ischemic heart disease in the past, the suggestion of "perform cardiovascular imaging examination first" is output; if the results of the cardiovascular imaging examination are abnormal, the suggestion of "perform treatment first to ensure that there are no ischemic symptoms in the heart before performing assisted reproductive technology" is output; if symptoms of ischemic heart disease appear again during pregnancy, the suggestion of "start treatment for ischemic heart disease" is output; the cardiovascular imaging examination includes stress echocardiography and echocardiography.

[0028] Preferably, the medication recommendation submodule outputs medication recommendations based on medication contraindications for liver and kidney function, drug interaction information, medication contraindications during ART, and medication contraindications during pregnancy; the medication recommendations include drug interaction risk recommendations and drug usage and dosage risk recommendations.

[0029] Preferably, the drug interaction risk recommendation is obtained by judging the clinical significance of drug interactions in the medication regimen based on drug interaction data, including: the drugs in the medication regimen are prohibited from being used in combination, otherwise it will seriously affect the effectiveness and safety of the drugs; the risk of drug combination in the medication regimen is serious, and the combination should be used with caution when necessary, which will moderately affect the effectiveness and safety of the drugs; the risk of drug combination in the medication regimen is moderate, and the drugs can be used in combination, which will slightly affect the effectiveness and safety of the drugs; the risk of drug combination in the medication regimen is slight, and the drugs can be used in combination, which will not affect the effectiveness and safety of the drugs; the risk of drug combination in the medication regimen is unknown, and there is currently insufficient evidence to clarify the risk level of drug combination.

[0030] Preferably, the drug usage and dosage risk recommendation is obtained by judging the usage and dosage of drugs in the medication regimen based on the patient's basic information data, contraindications to medication for liver and kidney function, contraindications to medication during ART and pregnancy (PLLR (pregnancy and lactation labeling rules), TERIS data (teratogenic risk information data)) and drug interaction data, including: the use of drugs in the medication regimen is prohibited, resulting in an extremely high risk of fetal malformation; the dosage of drugs in the medication regimen has a drug treatment risk, the drug needs to be used in a reduced dose, and a recommended dosage of the drug is given; the dosage of drugs in the medication regimen has a drug treatment risk, the drug needs to be used in an increased dose, and a recommended dosage of the drug is given; there is no problem with the dosage of drugs in the medication regimen and no adjustment is required; more preferably, for easy distinction, the drug dosage risk recommendations can be marked with different colors, such as: red means the drug is prohibited, yellow means there is a drug treatment risk and the dosage needs to be reduced, blue means there is a drug treatment risk and the dosage needs to be increased, and green means there is no problem with the drug dosage.

[0031] Preferably, the lifestyle and diet advice module outputs lifestyle and diet advice based on the symptom and sign data during pregnancy and the lifestyle and diet precautions during pregnancy.

[0032] In order to achieve the above-mentioned purpose of the invention, further, the present invention also provides a method for auxiliary management of pregnancy risks based on cardiovascular diseases, and the method for auxiliary management of pregnancy risks is implemented based on the above-mentioned auxiliary management system of pregnancy risks.

[0033] Preferably, the pregnancy risk auxiliary management method comprises the following steps: (1) Enter the patient's relevant basic data into the pregnancy risk auxiliary management system through the patient information interaction module; (2) Based on the input patient-related basic data, the assessment module assesses the pregnancy risk and outputs the pregnancy risk assessment results and recommendations on whether to continue ART; (3) Receive and review the pregnancy risk assessment results and the recommendation on whether to continue ART output by the assessment module through the physician information interaction module, and then send the reviewed pregnancy risk assessment results and the recommendation on whether to continue ART to the patient information interaction module and the follow-up management module; (4) The follow-up management module outputs follow-up management recommendations based on the pregnancy risk assessment results and patient-related basic data; (5) The physician information interaction module receives and reviews the follow-up management suggestions output by the follow-up management module, and then sends the reviewed follow-up management suggestions to the patient information interaction module.

[0034] The present invention provides a method for auxiliary management of pregnancy risks based on cardiovascular diseases. The auxiliary management system of pregnancy risks can automatically evaluate the pregnancy risks of patients and provide follow-up management suggestions based on the relevant basic data of the patients, which significantly improves the efficiency of physicians and pharmacists in evaluating and managing the cardiovascular risks of patients receiving ART, saving time for doctors and patients. At the same time, the management method of the present invention can not only timely prevent the risks related to cardiovascular diseases in patients, but also help to improve the success rate of ART in CVD patients; it can also reduce adverse pregnancy outcomes and reduce the pregnancy risks of CVD patients during the ART process, and is suitable for large-scale promotion and application.

[0035] Compared with the prior art, the present invention has the following beneficial effects: 1. The pregnancy risk auxiliary management system of the present invention can conduct targeted assessment of the patient's pregnancy risk and give corresponding follow-up management suggestions, which significantly improves the accuracy, comprehensiveness and reliability of the follow-up management suggestions, and helps to achieve more timely and effective follow-up management of the patient's related risks of cardiovascular diseases during pregnancy. It is suitable for large-scale application in pregnancy risk auxiliary management based on cardiovascular diseases.

[0036] 2. The pregnancy risk auxiliary management system of the present invention can automatically assess the patient's pregnancy risk and give corresponding follow-up management suggestions based on the patient's relevant information data, which significantly improves the efficiency of physicians and pharmacists in assessing and managing the cardiovascular risks of patients receiving ART, and greatly saves the time of doctors and patients.

[0037] 3. The pregnancy risk auxiliary management method of the present invention can effectively assist physicians in taking timely and effective precautions against cardiovascular disease-related risks in patients, help improve the success rate of ART in CVD patients and reduce the pregnancy risk of CVD patients during the ART process, thereby significantly reducing adverse pregnancy outcomes, and is suitable for large-scale application in the pregnancy risk auxiliary management of patients with cardiovascular diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1This is a schematic diagram of the structure of the pregnancy risk auxiliary management system based on cardiovascular diseases in Example 1 of the present invention; Figure 2 This is a flow chart of the method for auxiliary management of pregnancy risks based on cardiovascular diseases in Example 2 of the present invention. DETAILED DESCRIPTION

[0039] In order to more clearly describe the invention purpose, technical scheme and technical effect advantages in the specific implementation case of the present invention, the scheme in the specific embodiment of the present invention will be described in detail below. The specific technical scheme involved in the following specific embodiments is only for a clear and complete description of the innovative technical scheme of the present invention. It is only a part of the specific implementation scheme that can be adopted by the present invention, not all embodiments, and should not be understood as a limitation on the innovative scheme of the present invention. Any scheme adopting the same inventive concept of the present invention should be included in the protection scope of the present invention.

[0040] For those skilled in the art, when understanding the solutions described in the specific embodiments of the present invention, they can refer to the conventional technical manuals in the field. At the same time, for the places where the above-mentioned terms appear, they can make appropriate understandings or adjustments for reference, and deduce the implementation of the same or similar technical solutions without paying any creative work.

[0041] Example 1 A pregnancy risk auxiliary management system based on cardiovascular disease (structure such as Figure 1 As shown in Figure 1), it is mainly composed of system management module, evaluation module, follow-up management module, information interaction module and support database; Among them, the system management module is used to assist in the basic maintenance and settings of the management system; The system management module includes a data backup and recovery submodule, a user authority setting submodule and a pregnancy data recording submodule; the user authority setting submodule is used to grant login permissions according to set values ​​(such as physician or pharmacist level); the data backup and recovery submodule is used to record data loss due to unexpected situations to ensure data integrity; the pregnancy data recording submodule is used to record data information related to the pregnancy process of each patient to facilitate data backup, organization and review.

[0042] Among them, the assessment module is used to assess the patient's pregnancy risk based on the patient-related basic data collected by the patient information interaction module, and output the pregnancy risk assessment results and recommendations on whether to continue ART; The patient's relevant basic data includes at least one of basic information, liver and kidney function level, pregnancy symptoms and signs, and diagnosis and treatment plan; basic information includes the patient's name, age, ID number, previous medical history, previous medication history, and drug allergy history; symptoms and signs during pregnancy include gestational age data, dietary information, exercise information, and test results; diagnosis and treatment plan includes doctor's advice and medication plan; the liver and kidney function level is evaluated based on clinical test data and the patient's basic information; The pregnancy risk assessment results include: high-risk pregnancy, moderate-risk pregnancy and low-risk pregnancy; if the patient's mWHO risk grade is greater than or equal to grade III, the total ZAHARA score is greater than 2 points, or the CARPREG score is greater than or equal to 1 point, the pregnancy risk assessment result of "high-risk pregnancy" is output; if the patient's CARPREG score is less than 1 point, and the mWHO risk grade is grade II, or the total ZAHARA score is less than 2 and greater than 0.5 points, the pregnancy risk assessment result of "moderate-risk pregnancy" is output; if the patient's CARPREG score is less than 1 point, and the mWHO risk grade is grade I and the total ZAHARA score is less than or equal to 0.5 points, the pregnancy risk assessment result of "low-risk pregnancy" is output.

[0043] The assessment module outputs a recommendation on whether to perform ART based on the pregnancy risk assessment results; including: if the pregnancy risk assessment result is "high risk pregnancy", the recommendation of "not recommending to continue with ART" is output; if the pregnancy risk assessment result is "medium risk pregnancy and low risk pregnancy", the recommendation of "can continue with ART" is output.

[0044] Among them, the follow-up management module is used to output follow-up management suggestions based on the patient's relevant basic data and pregnancy risk assessment results; the follow-up management module includes a treatment management suggestion submodule, a medication suggestion submodule and a life and diet suggestion submodule; the follow-up management suggestions include treatment management suggestions, medication suggestions and life and diet suggestions; The treatment management recommendation submodule outputs treatment management recommendations based on the patient's pregnancy risk assessment results; including: if the pregnancy risk assessment result is low risk, the recommendation to "perform 1-2 pregnancy risk assessments during pregnancy" is output; if the pregnancy risk assessment result is medium risk, the recommendation to "perform a pregnancy risk assessment at least once every 3 months during pregnancy" is output; if the assessment result is high risk, the recommendation to "not continue the pregnancy or perform a pregnancy risk assessment once a month" is output.

[0045] The medication recommendation submodule outputs medication recommendations based on medication contraindications for liver and kidney function, drug interaction information, medication contraindications during ART, and medication contraindications during pregnancy; medication recommendations include drug interaction risk recommendations and drug usage and dosage risk recommendations; The drug interaction risk recommendation is based on the clinical significance of the drug interaction in the medication regimen based on the drug interaction data, including: the drugs in the medication regimen are prohibited from being used in combination, otherwise the effectiveness and safety of the drugs will be seriously affected; the risk of drug combination in the medication regimen is serious, and the combination should be used with caution when necessary, which will moderately affect the effectiveness and safety of the drugs; the risk of drug combination in the medication regimen is moderate, and the drug combination can be used, which will slightly affect the effectiveness and safety of the drugs; the risk of drug combination in the medication regimen is slight, and the drug combination can be used, which will not affect the effectiveness and safety of the drugs; the risk of drug combination in the medication regimen is unknown, and there is currently insufficient evidence to determine the risk level of drug combination; The risk recommendations for drug usage and dosage are based on the patient's basic information data, contraindications to medication for liver and kidney function, contraindications to medication during ART and pregnancy (PLLR (pregnancy and lactation labeling rules), TERIS data (teratogenic risk information data)) and drug interaction data to determine the usage and dosage of drugs in the medication regimen, including: the drugs in the medication regimen are prohibited from use, resulting in an extremely high risk of fetal malformation; there is a drug treatment risk in the dosage of the drugs in the medication regimen, the drugs need to be used in a reduced dose, and the recommended dosage of the drugs is given; there is a drug treatment risk in the dosage of the drugs in the medication regimen, the drugs need to be used in an increased dose, and the recommended dosage of the drugs is given; there is no problem with the dosage of the drugs in the medication regimen and no adjustment is required.

[0046] The lifestyle and diet advice module outputs lifestyle and diet advice based on the symptom and sign data during pregnancy and the lifestyle and diet precautions during pregnancy.

[0047] Among them, the information interaction module includes a patient information interaction module and a physician information interaction module; The information interaction module includes an input module and a receiving and displaying module; the input module is used to input relevant data; the receiving and displaying module is used to receive and display relevant data; The patient information interaction module is used to input patient-related basic data and receive the pregnancy risk assessment results output by the assessment module, the advice on whether to continue ART, and the follow-up management suggestions output by the follow-up management module; The physician information interaction module is used to receive and review the pregnancy risk assessment results output by the assessment module, the recommendations on whether to continue ART, and the follow-up management recommendations output by the follow-up management module.

[0048] Among them, the support database is used to provide data support for the evaluation module and follow-up management module, including: drug interaction data, contraindications for liver and kidney function medication, contraindications for medication during ART, contraindications for medication during pregnancy, and dietary precautions during pregnancy.

[0049] In the preferred embodiment, the input module includes an automatic import submodule and a custom input module; the automatic import submodule is used to automatically import patient-related information; the custom input module is used for users to enter patient-related information by themselves.

[0050] In the preferred embodiment, the custom entry module includes an image recognition entry module and a manual entry module; the image recognition entry module refers to a functional module that can scan or take pictures, use OCR technology to automatically identify the text content in the picture and convert it into an editable text format, thereby realizing automatic entry; the manual entry module refers to a functional module that requires the user to enter information word by word through the keyboard to realize entry, and is suitable for scenarios that cannot be recognized by OCR or require high-precision proofreading.

[0051] In a preferred embodiment, the manual input module can also be used by the patient to manually correct the data that cannot be recognized or is recognized incorrectly during the input process of the image recognition module, especially to correct the units of the data.

[0052] In the preferred solution, the physician information interaction module includes an obstetrician side, a cardiologist side and a pharmacist side; physicians can view and review patient-related data through the physician information interaction module.

[0053] In the preferred embodiment, the result is calculated using the creatinine clearance calculation formula, and the renal function level is judged according to the range of the result; the liver function level is judged using the Child-Pugh grading standard.

[0054] In a preferred embodiment, treatment management recommendations also include treatment management recommendations for patients with specific cardiovascular diseases or cardiovascular high risk factors, including: If the patient has a history of venous thromboembolism after or without hormone exposure, the recommendation is output to "start thromboprophylaxis at the beginning of ovarian gonadotropin stimulation"; if ovarian hyperstimulation syndrome occurs, the recommendation is output to "start preventive anticoagulation therapy"; if the patient still develops venous thromboembolism during pregnancy after the above measures, the recommendation is output to "start therapeutic anticoagulation"; If the patient has a history of hyperlipidemia, the output is "all hyperlipidemia drugs can continue to be used during gamete retrieval, no special monitoring is required during assisted reproductive technology, and attention should be paid to monitoring atherosclerotic cardiovascular disease (ASCVD) that may be caused by hyperlipidemia during pregnancy." If ASCVD occurs during pregnancy, the output is "start ASCVD treatment"; If the patient has had a stroke before, the output is "the continuation or discontinuation of antiplatelet drugs should be determined based on the individual patient risk"; if the patient has another stroke during pregnancy, the output is "the treatment should be started based on the individual patient's stroke condition"; If the patient has a history of essential hypertension, the output is a suggestion of "optimizing blood pressure control to systolic blood pressure (SBP) below 130 mmHg and diastolic blood pressure (DBP) below 80 mmHg, and paying attention to monitoring for hypertensive disorders during pregnancy"; if the systolic blood pressure during pregnancy is higher than 155 mmHg, or the diastolic blood pressure is higher than 105 mmHg, the output is a suggestion of "starting antihypertensive treatment"; If the patient has or develops symptoms of ischemic heart disease in the past, the suggestion of "perform cardiovascular imaging examination first" is output; if the results of the cardiovascular imaging examination are abnormal, the suggestion of "perform treatment first to ensure that there are no ischemic symptoms in the heart before performing assisted reproductive technology" is output; if symptoms of ischemic heart disease appear again during pregnancy, the suggestion of "start treatment for ischemic heart disease" is output; the cardiovascular imaging examination includes stress echocardiography and echocardiography.

[0055] In the preferred embodiment, for easy distinction, the drug dosage risk recommendations can be marked with different colors, such as: red means the drug is contraindicated, yellow means there is a risk of drug treatment and the dosage needs to be reduced, blue means there is a risk of drug treatment and the dosage needs to be increased, and green means there is no problem with the drug dosage.

[0056] The pregnancy risk auxiliary management system of the present invention can automatically generate targeted pregnancy risk assessment results and follow-up management suggestions based on the patient's relevant basic data, which can not only significantly improve the evaluation and management efficiency of cardiovascular risks of patients receiving ART by physicians and pharmacists, and greatly save follow-up management time; but also significantly improve the accuracy, comprehensiveness and reliability of follow-up management suggestions, and help to provide more timely and effective follow-up management suggestions for related risks of cardiovascular diseases during pregnancy.

[0057] Example 2 A method for assisting management of pregnancy risk based on cardiovascular disease (process such as Figure 2 As shown), it is implemented based on the pregnancy risk auxiliary management system in Example 1; The specific steps include: (1) Enter the patient's relevant basic data into the pregnancy risk auxiliary management system through the patient information interaction module; (2) Based on the input patient-related basic data, the assessment module assesses the pregnancy risk and outputs the pregnancy risk assessment results and recommendations on whether to continue ART; (3) Receive and review the pregnancy risk assessment results and the recommendation on whether to continue ART output by the assessment module through the physician information interaction module, and then send the reviewed pregnancy risk assessment results and the recommendation on whether to continue ART to the patient information interaction module and the follow-up management module; (4) The follow-up management module outputs follow-up management recommendations based on the pregnancy risk assessment results and patient-related basic data; (5) The physician information interaction module receives and reviews the follow-up management suggestions output by the follow-up management module, and then sends the reviewed follow-up management suggestions to the patient information interaction module.

[0058] The pregnancy risk auxiliary management method of the present invention significantly improves the efficiency of physicians and pharmacists in assessing and managing cardiovascular risks of patients receiving ART, saving time for physicians and patients; at the same time, it can also timely prevent cardiovascular disease-related risks in patients, help improve the success rate of ART in CVD patients, reduce adverse pregnancy outcomes, and reduce the pregnancy risk of CVD patients during the ART process.

[0059] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A pregnancy risk auxiliary management system based on cardiovascular disease, characterized in that: It includes system management module, evaluation module, follow-up management module, information interaction module and supporting database; Wherein, the system management module is used to assist in the basic maintenance and settings of the management system; The assessment module is used to assess the patient's pregnancy risk based on the patient-related basic data collected by the patient information interaction module, and output the pregnancy risk assessment result and the recommendation on whether to continue ART; the patient-related basic data includes at least one of basic information, liver and kidney function level, pregnancy symptoms and signs, and diagnosis and treatment plan; the pregnancy risk assessment result includes: high-risk pregnancy, medium-risk pregnancy, and low-risk pregnancy; The follow-up management module is used to output follow-up management suggestions based on the patient's relevant basic data and pregnancy risk assessment results; the follow-up management module includes a treatment management suggestion submodule, a medication suggestion submodule and a life and diet suggestion submodule; the follow-up management suggestions include treatment management suggestions, medication suggestions and life and diet suggestions; the medication suggestions include drug interaction risk suggestions and drug usage and dosage risk suggestions; The information interaction module includes a patient information interaction module and a physician information interaction module; The patient information interaction module is used to input patient-related basic data and receive the pregnancy risk assessment results output by the assessment module, the advice on whether to continue ART, and the follow-up management advice output by the follow-up management module; The physician information interaction module is used to receive and review the pregnancy risk assessment results output by the assessment module, the advice on whether to continue ART, and the follow-up management advice output by the follow-up management module; The supporting database is used to provide data support for the evaluation module and the follow-up management module.

2. The pregnancy risk auxiliary management system based on cardiovascular disease according to claim 1, characterized in that: The system management module includes a data backup and recovery submodule, a user authority setting submodule and a pregnancy data recording submodule.

3. The pregnancy risk auxiliary management system based on cardiovascular disease according to claim 1, characterized in that: The basic information includes the patient's name, age, ID number, previous medical history, previous medication history and drug allergy history; the symptoms and signs during pregnancy include gestational age data, diet information, exercise information and test results; the diagnosis and treatment plan includes doctor's orders and medication plan; the liver and kidney function level is assessed based on clinical test data and the patient's basic information.

4. The pregnancy risk auxiliary management system based on cardiovascular disease according to claim 1, characterized in that: The assessment module scores and grades the patient's relevant basic data based on the mWHO risk assessment standard, the ZAHARA scoring standard and the CARPREG scoring standard, and outputs a pregnancy risk assessment result according to the scoring and grading results; including: if the patient's mWHO risk grade is greater than or equal to grade III, the total ZAHARA score is greater than 2 points, or the CARPREG score is greater than or equal to 1 point, then output a pregnancy risk assessment result of "high pregnancy risk"; if the patient's CARPREG score is less than 1 point, and the mWHO risk grade is grade II, or the total ZAHARA score is less than 2 and greater than 0.5 points, then output a pregnancy risk assessment result of "medium pregnancy risk"; if the patient's CARPREG score is less than 1 point, and the mWHO risk grade is grade I and the total ZAHARA score is less than or equal to 0.5 points, then output a pregnancy risk assessment result of "low pregnancy risk".

5. The pregnancy risk auxiliary management system based on cardiovascular disease according to claim 1, characterized in that: The assessment module outputs a recommendation on whether to perform ART based on the pregnancy risk assessment result; including: if the pregnancy risk assessment result is "high risk of pregnancy", output a recommendation of "not recommending to continue with ART"; if the pregnancy risk assessment result is "medium risk of pregnancy and low risk of pregnancy", output a recommendation of "can continue with ART".

6. The pregnancy risk auxiliary management system based on cardiovascular disease according to claim 1, characterized in that: The treatment management suggestion submodule outputs treatment management suggestions based on the patient's pregnancy risk assessment results; including: if the pregnancy risk assessment result is a low risk of pregnancy, then output a suggestion of "conducting 1-2 pregnancy risk assessments during pregnancy"; if the pregnancy risk assessment result is a medium risk of pregnancy, then output a suggestion of "conducting a pregnancy risk assessment at least once every 3 months during pregnancy"; if the assessment result is a high risk of pregnancy, then output a suggestion of "not recommending continuing the pregnancy or conducting a pregnancy risk assessment once a month".

7. The pregnancy risk auxiliary management system based on cardiovascular disease according to claim 1, characterized in that: The treatment management recommendations also include treatment management recommendations for patients with specific cardiovascular diseases or cardiovascular high risk factors, including: If the patient has a history of venous thromboembolism after or without hormone exposure, the recommendation is output to "start thromboprophylaxis at the beginning of ovarian gonadotropin stimulation"; if ovarian hyperstimulation syndrome occurs, the recommendation is output to "start preventive anticoagulation therapy"; if the patient still develops venous thromboembolism during pregnancy after the above measures, the recommendation is output to "start therapeutic anticoagulation"; If the patient has hyperlipidemia in the past, the output is "all hyperlipidemia drugs can continue to be used during gamete retrieval, no special monitoring is required during assisted reproductive technology, and attention should be paid to monitoring ASCVD that may be caused by hyperlipidemia during pregnancy"; if ASCVD occurs during pregnancy, the output is "start ASCVD treatment"; If the patient has had a stroke before, the output is "the continuation or discontinuation of antiplatelet drugs should be determined based on the individual patient's risk"; if the patient has another stroke during pregnancy, the output is "treatment should be initiated based on the individual patient's stroke condition"; If the patient has a history of essential hypertension, the output is the suggestion of "optimizing blood pressure control to systolic pressure below 130 mmHg and diastolic pressure below 80 mmHg, and paying attention to monitoring for hypertensive disorders complicating pregnancy"; if the systolic blood pressure during pregnancy is higher than 155 mmHg, or the diastolic blood pressure is higher than 105 mmHg, the output is the suggestion of "starting antihypertensive treatment"; If the patient has or develops symptoms of ischemic heart disease in the past, the system will output the suggestion of "perform cardiovascular imaging examination first"; if the results of cardiovascular imaging examination are abnormal, the system will output the suggestion of "perform treatment first to ensure that there are no ischemic symptoms in the heart before performing assisted reproductive technology"; if symptoms of ischemic heart disease appear again during pregnancy, the system will output the suggestion of "start treatment for ischemic heart disease".

8. The pregnancy risk auxiliary management system based on cardiovascular disease according to claim 1, characterized in that: The drug interaction risk recommendation is obtained by judging the clinical significance of drug interactions in the medication regimen based on drug interaction data, and includes: the drugs in the medication regimen are prohibited from being used in combination, otherwise it will seriously affect the effectiveness and safety of the drugs; the risk of drug combination in the medication regimen is serious, and the drug combination should be used with caution when necessary, which will moderately affect the effectiveness and safety of the drugs; the risk of drug combination in the medication regimen is moderate, and the drug combination can be used, which will slightly affect the effectiveness and safety of the drugs; the risk of drug combination in the medication regimen is slight, and the drug combination can be used, which will not affect the effectiveness and safety of the drugs; the risk of drug combination in the medication regimen is unknown, and there is currently insufficient evidence to clarify the risk level of drug combination.

9. The pregnancy risk auxiliary management system based on cardiovascular disease according to claim 1, characterized in that: The risk recommendations for drug usage and dosage are based on the patient's basic information data, contraindications to medication for liver and kidney function, contraindications to medication during ART and pregnancy, and drug interaction data to determine the usage and dosage of drugs in the medication regimen, including: the drugs in the medication regimen are prohibited from use, resulting in an extremely high risk of fetal malformations; there is a drug treatment risk in the dosage of the drugs in the medication regimen, the drugs need to be used in a reduced dose, and a recommended dosage of the drugs is given; there is a drug treatment risk in the dosage of the drugs in the medication regimen, the drugs need to be used in an increased dose, and a recommended dosage of the drugs is given; there is no problem with the dosage of the drugs in the medication regimen and no adjustment is required.

10. A method for assisting management of pregnancy risks based on cardiovascular disease, characterized in that: The method is implemented based on the pregnancy risk auxiliary management system according to any one of claims 1 to 9, and comprises the following steps: (1) Enter the patient's relevant basic data into the pregnancy risk auxiliary management system through the patient information interaction module; (2) Based on the input patient-related basic data, the assessment module assesses the pregnancy risk and outputs the pregnancy risk assessment results and recommendations on whether to continue ART; (3) Receive and review the pregnancy risk assessment results and the recommendation on whether to continue ART output by the assessment module through the physician information interaction module, and then send the reviewed pregnancy risk assessment results and the recommendation on whether to continue ART to the patient information interaction module and the follow-up management module; (4) The follow-up management module outputs follow-up management recommendations based on the pregnancy risk assessment results and patient-related basic data; (5) The physician information interaction module receives and reviews the follow-up management suggestions output by the follow-up management module, and then sends the reviewed follow-up management suggestions to the patient information interaction module.

Images